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Abstract
Sepsis is a significant cause of morbidity and mortality in neonates
and adults, and the mortality rate doubles in patients who develop
cardiovascular dysfunction and septic shock. Sepsis is especially
devastating in the neonatal population, as it is one of the leading
causes of death for hospitalized infants. In the neonate, there are
multiple developmental alterations in both the response to
pathogens and the response to treatment that distinguish this age
group from adults. Differences in innate immunity and cytokine
response may predispose neonates to the harmful effects of pro-
inflammatory cytokines and oxidative stress, leading to severe
organ dysfunction and sequelae during infection and inflammation.
Underlying differences in cardiovascular anatomy, function and
response to treatment may further alter the neonate’s response to
pathogen exposure. Unlike adults, little is known about the cardio-
vascular response to sepsis in the neonate. In addition, recent
research has demonstrated that the mechanisms, inflammatory
response, response to treatment and outcome of neonatal sepsis
vary not only from that of adults, but vary among neonates based
on gestational age. The goal of the present article is to review key
pathophysiologic aspects of sepsis-related cardiovascular
dysfunction, with an emphasis on defining known differences
between adult and neonatal populations. Investigations of these
relationships may ultimately lead to ‘neonate-specific’ therapeutic
strategies for this devastating and costly medical problem.
Introduction
Sepsis is a significant cause of morbidity and mortality in
neonates and adults, and the mortality rate from sepsis
doubles in patients who develop cardiovascular dysfunction
and septic shock [1]. Annual combined deaths from sepsis
of patients of all ages equal the number of deaths from
myocardial infarction [2], and 7% of all childhood deaths
result from sepsis alone [3]. Sepsis is especially
devastating in the neonatal population, as it is responsible
for 45% of late deaths in the neonatal intensive care unit,
making it one of the leading causes of death for hospitalized
infants [4].
The incidence of sepsis is age-related, and is highest in
infants (5.3/1,000) and the elderly over 65 years of age
(26.2/1,000) [2]. Although the incidence is highest in the
elderly, both the intensive care unit admission rates (58.5%
versus 40%) and the average costs ($54,300 versus
$14,600) are higher in infants [2]. Twenty-one percent of
very low birthweight infants will develop at least one episode
of culture-proven bloodstream sepsis after the first 3 days of
life [5], and the septic episode will probably be more severe
than in adults [3]. In very low birthweight infants, sepsis
increases the hospital stay by 30% and increases mortality
2.5 times [5].
Unlike adults, little is known about the cardiovascular
response to sepsis in the neonate. Baseline neonatal cardio-
vascular function has not been well defined, and studies of
inotrope use to treat hypotension in neonates have failed to
show any improvement in short-term or long-term clinical
outcomes [6]. In addition, recent research has demonstrated
that the clinical presentation, mechanisms, inflammatory
response, response to treatment and outcome of neonatal
sepsis vary not only from that of adults, but vary among
neonates based on gestational age. The goal of the present
article is to review key pathophysiologic aspects of sepsis-
related cardiovascular dysfunction, with an emphasis on
defining known differences between adult and neonatal
populations. The potential impact of these differences on
therapeutic strategies is also discussed.
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Innate immunity/inflammatory response
Underlying the differences in neonatal and adult sepsis are
alterations in the developing immune system. These differ-
ences include innate and acquired immunity, immune cell
numbers and function, cytokine elaboration and the inflam-
matory response.
The influence of perinatal factors on the development and
response to sepsis is unique to newborns. Challenges to the
maternal immune system before and during pregnancy have
been associated with modulation of the neonatal immune
response, and this modulation occurs in both humoral and
cell-mediated immunity [7]. Although proinflammatory cyto-
kines such as TNFα, IL-1β and IL-6 have not been shown to
cross the human term placenta [8], certain immunoglobulins
and lymphoid cells can cross the placenta and change fetal
and postnatal immune development [7]. The transplacental
transfer of immunoglobulins, however, does not occur until
32 weeks gestation [9], leading to a relative immune
deficiency in extremely premature infants. Labor of any
duration may be immunologically beneficial to the neonate,
with improved neutrophil survival and lipopolysaccharide
(LPS) responsiveness [10]. Labor itself is a mild pro-
inflammatory state and has been associated with delayed
neutrophil apoptosis, fetal leukocytosis and elevation of the
systemic neutrophil count when compared with cesarean
section without labor [10]. In addition, respiratory burst,
CD11b/CD18 and IL-8 receptors have all been shown to be
increased after vaginal delivery in comparison with cesarean
section [11].
Cytokines
Severe infection can induce the systemic inflammatory
response syndrome and can lead to the development of
septic shock, which is associated with elevated levels of
proinflammatory cytokines including IL-1β, IL-6, IL-8 and
TNFα [12]. LPS is a cell wall component of Gram-negative
bacteria, and is the main endotoxin implicated in the initiation
of the proinflammatory response [13]. If this extreme
inflammatory response is not counterbalanced by a competent
compensatory anti-inflammatory response syndrome, the
resultant exaggerated inflammatory response leads to
increased morbidity and mortality during sepsis [14]. The
concentration of proinflammatory cytokines is higher in
patients with septic shock than in those with severe sepsis,
and elevated levels of IL-1β, IL-6 and IL-8 are associated with
an increase in early mortality (<48 hours) [12]. Sepsis also
has the potential to develop into a bimodal disease initially
characterized by a proinflammatory state and progressing to
a state of immune suppression and immunoparalysis [15,16],
which is related to increased production of IL-10 [17] and
decreased HLA-DR expression [18]. The resultant immune
suppression appears to be confined to the blood compart-
ment, however, while a hyperinflammatory state persists in
tissues, which makes defining the role of cytokines in sepsis
more difficult [19].
The inflammatory cytokine response to sepsis differs in
neonates and adults. Although premature infants were once
believed to have deficient production of proinflammatory
cytokines, intrauterine fetal cord blood samples taken between
21 and 32 weeks gestation have demonstrated significant
synthesis of IL-6, IL-8 and TNFα [20]. Term and preterm
infants have been shown to have a higher percentage of IL-6-
positive and IL-8-positive cells than adults, with preterm
infants having the highest percentage of IL-8-positive cells
[21]. After stimulation with LPS, this increased percentage of
proinflammatory cells in neonates is more pronounced and
occurs faster than in adults. In addition, the compensatory
anti-inflammatory response system in neonates appears to be
immature, with both term and preterm infants demonstrating
profoundly decreased IL-10 production and a lower amount
of transforming growth factor beta-positive lymphocytes than
do adults after LPS stimulation [14]. Although there is a
decrease in the absolute amount of IL-10 produced, an
increase in the IL-10:TNFα ratio has been reported in
premature infants after LPS exposure; an increased
IL-10:TNFα ratio in critically ill adults has been shown to be a
negative predictor of outcome [22]. These perinatal and
developmental influences on innate immunity and the
inflammatory response may significantly alter the neonate’s
response to pathogen exposure.
Neutrophils
In addition to cytokine differences in the neonate, eosinophils,
macrophages and polymorphonuclear neutrophils have
reduced surface binding components and have defective
opsonization, phagocytosis and antigen-processing capabili-
ties, leading to a generally less robust response to pathogen
exposure. Polymorphonuclear neutrophil function is the
primary line of defense in the cellular immune system, and
there is an alteration in both neutrophil function and survival in
neonates versus adults. Neonates, especially those born
prematurely, display a pattern of infectious diseases similar to
the pattern seen in older individuals with severe neutropenia
[20], have a markedly decreased neutrophil storage pool and
cell mass [23,24], and are more likely to develop neutropenia
during systemic infection [25]. Functional deficiencies of
neutrophils in preterm and stressed/septic neonates include
chemotaxis [26], endothelial adherence [20], migration [27],
phagocytosis and bactericidal potency [20,28,29]. The
NADPH oxidase system, however, may be a first-line
mechanism of innate immunity as there is a direct negative
correlation between oxidative burst product generation and
gestational age [20]. This could, however, have a detrimental
effect on preterm infants as exaggerated oxygen free radical
formation may contribute to the development of such
neonatal diseases as retinopathy of prematurity and broncho-
pulmonary dysplasia, as well as to cardiovascular disease.
Cardiovascular dysfunction in sepsis
Sepsis is clinically characterized by systemic inflammation,
cardiovascular dysfunction, an inability of oxygen delivery toPage 3 of 9
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meet oxygen demand, an altered substrate metabolism and,
ultimately, multiorgan failure and death [30]. The mortality rate
from sepsis doubles in patients who develop cardiovascular
dysfunction and septic shock [1]. Little is known about the
cardiovascular effects of sepsis in the neonate, but the
developing cardiomyocyte differs from that of the adult and
may lead to differences in the cardiac response to sepsis and
inflammation. In addition to underlying differences in the
structure of the neonatal cardiomyocyte, functional alterations
in proliferative activity [31] and excitation–contraction coup-
ling [32] have been identified. These differences may be
mediated by alterations in calcium channel expression and
activity [33,34], in ATP-sensitive potassium channel function
[35] and in β-receptor coupling [36], and may contribute to
differences in sepsis outcomes and therapeutic responses in
neonates versus adults.
Cardiac dysfunction and cardiovascular collapse during sepsis
result from increased levels of TNFα [37] and from increased
cardiac myocyte production of nitric oxide and peroxynitrite
[38], which leads to further DNA damage and ATP depletion
[39], resulting in secondary energy failure [40]. In addition,
serum from patients with septic shock directly causes a
decreased maximum extent and peak velocity of contraction,
activates transcription factors for proinflammatory cytokines
and induces apoptosis in cultured myocytes [41]. LPS-
induced production of TNFα has been associated with
increased apoptosis and cell death in adult cultured
cardiomyocytes [42], and this ventricular myocyte apoptosis
has been linked to cardiovascular dysfunction in adult whole
animal experiments [43]. Neonatal cardiomyocytes, however,
do not exhibit an increase in apoptosis despite an increase in
TNFα production after LPS exposure, suggesting another
mechanism for sepsis-associated cardiovascular dysfunction
in neonates [44].
Septic shock is characterized in adults by a hyperdynamic
phase with decreased left ventricular ejection fraction,
decreased systemic vascular resistance and an increased
cardiac index [45,46]. Underlying coronary artery disease,
cardiomyopathy and congestive heart failure may contribute
to the systolic and diastolic ventricular dysfunction described
in the setting of adult sepsis. The resultant myocardial
depression does not appear to be related to ischemia,
however, as the coronary blood flow and coronary sinus
lactate levels have been found to be normal in patients with
septic shock [47,48].
Myocardial dysfunction in childhood septic shock reaches its
maximum within hours and is the main cause of mortality
[30,49]. In comparison with adults, children more often
present in a nonhyperdynamic state with decreased cardiac
output and increased systemic vascular resistance [46,50]
and can develop this nonhyperdynamic septic shock even
after fluid resuscitation [51]. This low cardiac output is
associated with an increase in mortality [52,53]. Owing to a
limited number of research studies in the very young, the
hemodynamic response of premature infants and neonates is
not well understood, and the presenting hemodynamic
abnormalities are more variable than in older children and
adults [50]. Complicating the clinical evaluation of these
patients is the observation that blood pressure is a poor
indicator of systemic blood flow in neonates [6,54].
In both premature and full-term infants, left ventricular systolic
performance is highly dependent on afterload, which may
increase the susceptibility of neonates to sudden cardiac
deterioration in the setting of shock and vasoconstriction
[55,56]. Newborn infants also have a relatively decreased left
ventricular muscle mass [57] and an increased ratio of type I
collagen (determinant of tissue rigidity) to type III collagen
(provides elasticity) in myocardial tissue [58], which may
account for the impaired left ventricular diastolic function and
the alterations in mid-wall left ventricular fractional shortening
seen in premature infants [59]. These physiologic abnor-
malities, coupled with the finding that the neonatal left
ventricular myocardium already functions at a higher baseline
contractile state [55], may limit the neonate’s ability to
increase the stroke volume or myocardial contractility in the
setting of sepsis. Complicating the cardiovascular response
to sepsis in the neonate are additional morbidities, including
reopening of a patent ductus arteriosus and the development
of persistent pulmonary hypertension of the newborn due to
cytokine elaboration, acidosis and hypoxia in the setting of
sepsis [52]. These underlying differences in anatomy, physio-
logy and adaptive cardiovascular function exemplify the need
to more specifically identify and understand the cardio-
vascular response to sepsis in the neonate in order to
develop successful therapeutic strategies.
Treatment
The short-term goal of treatment is to optimize the perfusion
and delivery of oxygen and nutrients, to correct and/or
prevent metabolic derangements resulting from cellular hypo-
perfusion and to support organ and body functions until
homeostasis is achieved [30,60]. Although our understanding
of the pathophysiologic mechanisms of sepsis and septic
shock has improved over the past 10 years, the mortality and
morbidity associated with sepsis continues to be high
[2,30,46]. Proinflammatory cytokines have been implicated in
the pathogenesis of organ dysfunction during sepsis, but the
modulation of single gene products (TNFα, IL-1β, inducible
nitric oxide synthase) and nonpeptide mediators (platelet-
activating factor, prostaglandin or leukotriene inhibitors) has
not been shown to improve mortality in sepsis and septic
shock [41].
Unlike adult and pediatric critical medicine, where there are
extensively studied multiple organ dysfunction scores and
well-defined algorhythmic guidelines for treatment [61], there
is a large amount of practice variability in neonatal sepsis. The
American College of Critical Care Medicine concluded that
Available online http://ccforum.com/content/11/5/228the adult guidelines for hemodynamic support of septic shock
are not applicable to children and neonates, and published
guidelines for these younger age groups [52]. Premature
neonates, however, were not specifically addressed.
Antibiotics
Empiric therapy aimed at the most probable causative
pathogens should be started immediately upon suspicion of
clinical sepsis, as a delay in the initiation of antibiotics has
been associated with an increased risk of mortality in both
pediatric [30,62] and adult [13,63,64] patients with sepsis. In
neonates, special developmental characteristics such as
immaturity of the hepatic and renal clearance systems need
to be considered when prescribing an antibiotic regimen.
Fluid resuscitation
Fluid resuscitation is an important mainstay in the resusci-
tation of patients with septic shock, as marked hypovolemia
may result from vasodilation and increased capillary leak. A
significant reduction in mortality has been demonstrated
when hemodynamic function is optimized within the first few
hours after presentation of sepsis [60]. There has been
longstanding debate about the use of colloids or crystalloids,
but there is currently no strong evidence supporting the
superiority of either fluid agent in the resuscitation of septic
shock [13,65-68]. The underlying importance is the
maintenance of preload and tissue perfusion. Fluid resusci-
tation is necessary in premature infants, but must be provided
with caution due to the risks of developing intraventricular
hemorrhage from fluctuations in cerebral perfusion and
developing heart failure and/or pulmonary overcirculation
from resultant left to right flow through a patent ductus
arteriosus [52].
Cardiovascular agents
Adult sepsis is most often characterized by a hyperdynamic
state with vasodilation, while neonatal sepsis may be a
hypodynamic state with vasoconstriction and may respond
better to inotrope and vasodilator therapy [30]. In both the
recent recommendations of the American College of Critical
Care [69] and an extensive evidence-based review of
vasopressor support in septic shock [70], dopamine and
norepinephrine are considered first-line agents in adult septic
shock. An attenuated response to adrenergic stimulation has
been reported in patients with septic shock, which is thought
to result from the downregulation of receptors, uncoupling of
receptors from adenylate cyclase or decreased production of
cAMP [46]. This impaired effectiveness of exogenous
adrenergic stimulation may be augmented in neonates due to
a functionally immature autonomic nervous system [30,71]
and elevated baseline levels of catecholamines [72-75],
especially in premature infants.
Randomized controlled trials of vasopressors in neonates are
extremely rare. In a recent study investigating dopamine
versus epinephrine for cardiovascular support in low birth-
weight infants, both agents were found to be efficacious in
improving the mean arterial blood pressure – but epinephrine
was associated with more short-term adverse effects such as
enhanced chronotropic response, hyperglycemia requiring
insulin treatment and increased plasma lactate levels [76].
There is only a weak correlation between blood pressure and
systemic blood flow in neonates [6], and, although a recent
metanalysis found dopamine to be superior to dobutamine in
improving blood pressure, a randomized controlled trial
showed that dobutamine increased systemic blood flow more
effectively than dopamine [77]. According to recently
published clinical practice parameters, however, dopamine
remains the first-line agent in neonates, and epinephrine may
be used in dopamine-resistant septic shock [52]. If low
cardiac output and high systemic vascular resistance persist,
dobutamine and/or a type III phosphodiesterase inhibitor may
be indicated [46,52]. Phosphodiesterase inhibitors have the
additional benefits of TNFα attenuation and decreased
myocardial inducible nitric oxide synthase activity [46], and
milrinone has been shown to improve cardiovascular function
in pediatric patients with septic shock [78].
Milrinone is a selective phosphodiesterase type III inhibitor that
has proven safe and efficacious in certain clinical scenarios in
pediatric patients [78,79]. Many of these studies, however,
have been conducted by providing a loading dose of milrinone
followed by a continuous infusion. In practice, physicians often
forego the loading dose, especially in patients that may have
decreased preload to avoid any untoward hemodynamic
effects including undue hypotension. The time to reach steady
state is therefore prolonged compared with the
pharmacokinetics previously described [80]. Despite this
approach, many patients are concomitantly on catecholamine
infusions, which have a very short half-life. The glomerular
filtration rate in term neonates is 20 ml/min×1.73 m2, which is
generally twice that of premature newborns [81]. The
glomerular filtration rate improves over the first several weeks
of life in all newborns but the velocity at which it improves is
less in premature infants. In term newborns, the glomerular
filtration rate doubles in the first 2 weeks of life [82,83]. These
differences in glomerular filtration rate values among varying
gestational age newborns impact the administration of
medications that are primarily eliminated in the renal system.
This impact is pertinent in milrinone use, and therefore dosing
is often renally adjusted in neonates. In cases of persistent
pulmonary hypertension of the newborn associated with
sepsis, inhaled nitric oxide may help reduce pulmonary
vascular resistance and off-load the right ventricle.
Immunomodulating agents
Agents such as corticosteroids, pentoxifylline and recom-
binant human-activated protein C have been studied as
adjunctive treatments for sepsis in adults and neonates
(Table 1). Recombinant human-activated protein C is the only
adjunctive therapy approved for the treatment of severe
sepsis in adults who have a high risk of death [84,85].
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The use of corticosteroids in the management of sepsis has
evolved with the identification of relative adrenal insufficiency,
which occurs in 50–75% of patients with septic shock [13].
While adult studies of high-dose corticosteroids have not
shown a benefit or reduction in mortality [86], lower doses of
steroids given over a longer course may actually decrease
mortality in adult patients with sepsis [87]. The use of
corticosteroids in the treatment of sepsis in neonates and
children remains relatively untested. A recent study has
shown that 44% of children with septic shock are adrenally
insufficient [88], but a large cohort study of steroid
administration to children and infants with severe sepsis
showed no improvement in outcome and an increase in
mortality in a subset of patients [89]. In neonates, both
hydrocortisone and low-dose dexamethasone have been
Available online http://ccforum.com/content/11/5/228
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Table 1
Immunomodulating agents in neonatal and adult sepsis
Agent Neonates Adults
Steroids No evidence of improved outcome in critically  High-dose: no benefit [101] or reduction in mortality [102], 
ill infants or children with sepsis [89] may actually increase mortality [86]
Hemodynamically stable: no benefit [101]
Low-dose, long-course: may decrease mortality [87]
Intravenous  Prevention: 3% reduction in sepsis, 4% reduction  Polyclonal: significant reduction in mortality [105]
immunoglobulin in any serious infection; no change in mortality, 
necrotizing enterocolitis, bronchopulmonary dysplasia, 
intraventricular hemorrhage or length of stay [103]
Suspected infection: decrease in mortality of  Monoclonal: HA-1A, E5, IL-1, phospholipase A2, adhesion 
borderline statistical significance [104] molecules and contact factors all show no benefit [86]
Proven infection: no change in mortality [104]
Colony-stimulating  Treatment: rhG-CSF and rhGM-CSF not effective  rhG-CSF in pneumonia with severe sepsis: no difference in 
factors in reducing mortality [106,107] mortality, ARDS or adverse events [108,109]; no difference in 
days of ventilatory support or intensive care unit stay [108]
Prophylaxis: both agents effective in correcting  rhG-CSF in severe sepsis: small study shows a significant 
neutropenia in premature neonates [106 107];  decrease in mortality [110]
rhGM-CSF may decrease infection in infants 
<32 weeks who are neutropenic or at risk for 
developing neutropenia [106,107]; rhGM-CSF 
decreases mortality in neutropenic neonates with 
sepsis [107]
rhG-CSF febrile neutropenia: shorter hospital stay, no 
difference in mortality [111]
rhGM-CSF in severe sepsis: no change in mortality [112,113]; 
improved PaO2/FiO2 ratio [112] and clearance of infection 
[113]
Activated protein C No randomized trials in neonates [114,115] Severe sepsis and increased risk of death: improved organ 
function and decreased mortality [114]; 19.4% reduction in 
relative risk of death [84]; cost-effective [117]
Two case reports with survival without adverse  Severe sepsis and low risk of death: no benefit [118]
events [114,116]
Large pediatric clinical trial stopped early due to 
no improvement in mortality and increased 
intracranial hemorrhage [98]
Pentoxifylline Decreased mortality, circulatory compromise,  Improved cardiopulmonary function [96] and hemodynamic 
disseminated intravascular coagulopathy and  performance [95]
necrotizing enterocolitis versus placebo [94]
Reduces mortality without adverse effects [119] No change in 28-day mortality [95]
No adverse effects [95,96]
ARDS, acute respiratory distress syndrome; rhG-CSF, recombinant human granulocyte colony-stimulating factor; rhGM-CSF, recombinant human
granulocyte–macrophage colony-stimulating factor.shown to effectively increase blood pressure in refractory
hypotension [90,91], but steroids should be used with
caution as early administration of high-dose corticosteroids
has the additional risk of impaired neurodevelopment and
clinically significant disability later in life [92].
Pentoxifylline
Pentoxifylline is a methylxanthine derivative and nonspecific
phosphodiesterase inhibitor that has been shown to be
beneficial in the treatment of a variety of illnesses in all age
groups, but only a handful of studies have focused on the use
of pentoxifylline in the treatment of sepsis in adults and
neonates [93]. In premature neonates with sepsis, pentoxi-
fylline has been shown to decrease IL-6 and TNFα levels, to
decrease the clinical symptoms of necrotizing enterocolitis, to
reduce the development of cardiac, renal or hepatic failure, to
decrease the incidence of disseminated intravascular
coagulopathy and to improve blood pressure and survival
rates [94]. Adult studies have shown improved cardiopul-
monary and hemodynamic function in severe sepsis [95,96]
but did not show a reduction in 28-day mortality [96]. Both
neonatal and adult studies showed no adverse effects of the
medication.
Recombinant human-activated protein C
At least 80% of children and adults develop an acquired
deficiency of protein C during severe sepsis, and this
deficiency is associated with adverse outcomes, such as
multiple organ failure and mortality [97]. In the PROWESS
trial, the use of in the treatment of adults with severe sepsis
and a high risk of death showed a relative risk reduction of
mortality of 19% [84]. A large clinical trial in pediatric patients
with sepsis was stopped early due to a lack of demonstrated
benefit and the finding of an increased risk of intracranial
hemorrhage, especially in infants younger than 60 days of life
[98]. In addition to the potential risk for increased bleeding in
the neonatal population, the efficacy of recombinant human-
activated protein C may also be different in neonates due to
underlying developmental differences in the coagulation
pathway. The anticoagulant effect of recombinant human-
activated protein C has been shown to be decreased in
neonatal cord plasma, which is due, in part, to the lower
levels of tissue factor pathway inhibitor, antithrombin and
protein S in neonatal versus adult plasma [84,85].
Conclusion
The incidence of neonatal sepsis is significant, with
suspected sepsis being the most common diagnosis on
admission to the neonatal intensive care unit in the United
States [99]. Research regarding neonatal sepsis, and the
cardiovascular effects of sepsis in particular, is relatively
lacking. The cost of neonatal sepsis is high, with very low
birthweight infants and low birthweight infants with sepsis
consuming twice as much financial resource than do infants
with respiratory distress syndrome [3]. Future medical and
social resource utilization is also increased, as there is a
significant increase in the morbidity of infants surviving severe
infection, with a 30–400% odds increase of later neuro-
developmental impairment [100].
In the neonate, there are multiple developmental alterations in
both the response to pathogens and the response to treat-
ment that distinguish this age group from adults. Differences
in innate immunity and cytokine response may predispose
neonates to the harmful effects of proinflammatory cytokines
and oxidative stress, leading to severe organ dysfunction and
sequelae during infection and inflammation [14]. Underlying
differences in cardiovascular anatomy, function and response
to treatment may further alter the neonate’s response to
pathogen exposure. We must therefore gain a greater
understanding of these developmental changes in order to
adequately understand and treat immune and inflammatory-
related cardiovascular compromise in the neonatal popu-
lation. This remarkably unstudied area of neonatal sepsis is
paramount, as cardiac failure remains a main cause of death
in this disease state. Translational research will be the corner-
stone of this research initiative, as therapeutic agents will
need to be developmentally targeted in order to be effective.
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